Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript Summary
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $27
H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Raises Target Price to $28
Phathom Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Raises Target Price to $28